Interv Akut Kardiol. 2010;9(6):284-285

Role antiarytmik v éře elektroimpulzoterapie

Jan Lukl
1. interní klinika LF UP a FN Olomouc

-

Keywords: -

Published: December 10, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lukl J. Role antiarytmik v éře elektroimpulzoterapie. Interv Akut Kardiol. 2010;9(6):284-285.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bory M, Poggi I, d Journo J, Serradimigni A, Auder M. Prevention by propranolol of paroxysmal tachycardia of supraventricular origin. Long-term results. Arch Mal Vaiss 1970; 63: 174-181.
    2. Tonkin AM, Gallagher JJ, Wallace AG. Tachyarrhythmias in Wolff-Parkinson-White syndrome. JAMA 1976; 235: 947-949. Go to original source... Go to PubMed...
    3. Lemery R, Takajic M, Roy D, Fournier A, et al. Catheter ablation using radiofrequency or low-energy direct current in pediatric patiens with the Wolff-Parkinson-White syndrome. Am J Cardiol 1994; 73: 191-204. Go to original source... Go to PubMed...
    4. Macias Gallego A, Diaz-infante E, Garcia-Bolano I. Spanish catheter ablation registry. 8th official report of the spanisch society of cardiology working group on electrophysiology and arrhythmias (2008). Rev Esp Cardiol. 2009; 62: 1276-1285. Go to original source...
    5. Spector P, Reynolds MR, Calkins H, et al. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. Am J Cardiol 2009; 104: 671-677. Go to original source... Go to PubMed...
    6. Coplen SE, Altman EM, Berlin JA, et al. Efficacy and safety of quidine therapy for maintenance of sinus rhythm after cardioversion. A meta. analysis of randomized control trials. Circulation 1990; 82: 1106-1116. Go to original source... Go to PubMed...
    7. Roy D, Takajíc M, Connolly S, et al. Amiodarone to prezent recurrence of atrial fibrillation. Canadian trial of atrial fibrillation investigatorw. N Engl J Med 2000; 30(342): 913-920. Go to original source... Go to PubMed...
    8. Singh BN, Connolly SF, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 57: 987-999. Go to original source... Go to PubMed...
    9. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008; 117: 1518-1525. Go to original source... Go to PubMed...
    10. Roy D, Rowe BH, Stell IG, et al. A randomized, controlled trial of RSD1235, a novel antiarrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004; 44: 2355-2361. Go to original source... Go to PubMed...
    11. Haissaquerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Eng J Med 1998; 339: 59-666. Go to original source... Go to PubMed...
    12. Feinberg WM, Blackshear JL, Laupacis JL, et al. Prevalence, age distribution and gender in patiens with atrial fibrillation. Arch Intern Med 1995; 155: 469-473. Go to original source...
    13. Wyse DG, Hellstrom A,, McBride R, et al. Events in the cardiac arrythmia supression trial (CAST): mortality in patiens surviving open label tritration but not randomized to doubleblind therapy. J AM Coll Cardiol 1991; 18: 20-28. Go to original source... Go to PubMed...
    14. Higgins S. Impact of the multicenter automatic defibrillator implantation trial on implantable cardioverter defibrillator indication trends. Am J Cardiol 1999; 83: 79D-82D. Go to original source... Go to PubMed...
    15. Moss AJ, Daubert J, Dareba W. Madit II clinical implication. Card Electrophysiol Rev 2002; 4: 464-465.
    16. Wood P, ed: The heart and circulation, London. Eyre and Spottiswood, 1952; 114.

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.